The membrane actions of tranquilizers in relation to neuroleptic-induced parkinsonism and tardive dyskinesia.
D000818:Animals; D002118:Calcium / Q000378:metabolism; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D004912:Erythrocytes / Q000166:cytology; D005246:Feedback; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D008055:Lipids; D008566:Membranes / Q000187:drug effects; D008968:Molecular Conformation; D009069:Movement Disorders / Q000139:chemically induced*; D009407:Nerve Block; D010302:Parkinson Disease, Secondary / Q000139:chemically induced*; D010791:Phrenic Nerve / Q000187:drug effects; D011506:Proteins; D011618:Psychotic Disorders / Q000188:drug therapy; D011955:Receptors, Drug / Q000187:drug effects; D012964:Sodium / Q000378:metabolism; D012995:Solubility; D013499:Surface Properties; D009435:Synaptic Transmission / Q000187:drug effects; D014149:Tranquilizing Agents / Q000009:adverse effects* / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use; D014446:Tyrosine 3-Monooxygenase / Q000032:analysis
D008055:Lipids; D011506:Proteins; D011955:Receptors, Drug; D014149:Tranquilizing Agents; D012964:Sodium; D014446:Tyrosine 3-Monooxygenase; D002118:Calcium; D004298:Dopamine